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Introduction
============

The search and capture process by which kinetochores attach microtubules is stochastic; thus, the time taken from nuclear envelope breakdown (NEB) to alignment of the last kinetochore is highly variable ([@bib23]). However, sister separation at anaphase is a global event, triggered shortly after the anaphase-promoting complex (APC/C) initiates proteolysis of securin and cyclin B1 ([@bib4]; [@bib9]). Consequently, maintaining accurate chromosome segregation requires that the APC/C is restrained until the last kinetochore stably attaches microtubules. This is achieved by an inhibitory network called the spindle assembly checkpoint (SAC; [@bib21]).

The SAC consists of kinetochore-bound sensors, including Bub1, Mad1, and Mps1; a signal transducer known as the mitotic checkpoint complex, comprising BubR1, Bub3, Mad2, and Cdc20; and an effector, namely the APC/C ([@bib21]). Bub1, BubR1, and Mps1 are protein kinases, and, although phosphorylation appears to be integral to the SAC ([@bib22]), the specific roles of these kinases are far from clear. Indeed, kinase activity may not be required for checkpoint function itself; yeast strains harboring a Bub1 allele completely lacking the kinase domain are checkpoint proficient ([@bib31]).

Mps1, originally identified as a regulator of spindle pole body duplication in *Saccharomyces cerevisiae* ([@bib14]), is also essential for SAC function ([@bib33]). Some studies have probed the requirement for Mps1 kinase activity in SAC signaling, but the emergent picture is complex. One study, which used kinase-dead and analogue-sensitive Mps1 alleles, showed that budding yeast Mps1 activity was required for SAC function when kinetochores fail to attach microtubules ([@bib13]). However, a second study using the small-molecule inhibitor cincreasin demonstrated that Mps1 activity was required for checkpoint activation when attached kinetochores fail to come under tension ([@bib5]).

In vertebrates, the situation is equally complex. Consistent with a role in monitoring unattached kinetochores, reconstituting *Xenopus laevis* egg extracts with a kinase-dead Mps1 failed to restore the checkpoint ([@bib1]). In this system, Mps1 is required for kinetochore recruitment of Bub1, Bub3, BubR1, Mad1, Mad2, and centromere protein E (Cenp-E), thus providing a possible mechanism for Mps1 function ([@bib1]; [@bib34]; [@bib35]). However, this is at odds with experiments in human tissue culture cells: although RNAi-mediated repression of Mps1 results in a failure to recruit Mad1 and Mad2, other checkpoint components such as Bub1, BubR1, and Cenp-E appeared unaffected ([@bib15]).

Another surprising observation from RNAi studies is that Mps1 only appears to be required for SAC function after spindle damage and not during an unperturbed mitosis ([@bib27]; [@bib24]). Similarly, inhibition of Mps1 with the nonspecific JNK inhibitor, SP600125, results in SAC override, but only in the presence of spindle poisons ([@bib24]). In contrast, other vertebrate SAC components restrain mitosis in the absence of spindle damage ([@bib21]). Again, in contrast to the RNAi studies, SP600125 mislocalizes BubR1; its effect on Mad2 is unknown ([@bib24]).

These observations are also complicated by the fact that Mps1 plays multiple roles. In addition to spindle pole body duplication ([@bib8]), Mps1 is required for kinetochore--microtubule interactions ([@bib5]; [@bib13]), possibly via the phosphorylation of Dam1 ([@bib25]). In yeast, Mps1 promotes kinetochore biorientation by eliminating malorientations ([@bib18]). Human Mps1 may serve a similar function by regulating the aurora B kinase via phosphorylation of the chromosome passenger Borealin ([@bib12]).

In an attempt to reconcile these observations and dissect the role of Mps1 kinase activity in human cells, we established a complementation assay repressing endogenous Mps1 by RNAi followed by induction of RNAi-resistant Mps1 transgenes. Using time-lapse imaging of GFP-tagged chromosomes, we show that Mps1 kinase activity is required for SAC function during an unperturbed mitosis. Furthermore, we show that kinetochore localization of Mad2 but not Mad1 is acutely sensitive to the inhibition of Mps1 kinase activity.

Results and discussion
======================

shRNA-mediated repression of Mps1
---------------------------------

To define the role of Mps1 kinase activity in SAC function, we set up a complementation assay repressing endogenous Mps1 by RNAi while simultaneously expressing RNAi-resistant transgenes. To do this, we generated an anti-Mps1 antibody to monitor RNAi efficiency. This antibody detects a single protein of ∼95 kD and decorates prometaphase kinetochores, which is consistent with Mps1\'s known properties (Fig. S1, A and B; available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>). To inhibit Mps1, we screened a panel of short hairpin RNA (shRNA) vectors after transient transfection into HeLa cells. Immunoblotting and immunofluorescence identified one vector that efficiently repressed Mps1 (Fig. S1, C and D).

Quantitative immunoblotting indicated that Mps1 was repressed to \<20% of its normal level (unpublished data). Because the transfections were typically ∼75% efficient, this residual protein is largely caused by the untransfected cells. Indeed, quantitation of pixel intensities in transfected cells reveals that kinetochore-bound Mps1 is reduced to \<3% (Fig. S1 E). To determine whether this was sufficient to compromise Mps1 function, repressed HeLa cells were challenged with microtubule toxins for 18 h. While control cells arrested in mitosis, cells in the Mps1-RNAi population were in interphase, indicating SAC override (Fig. S1 F). Indeed, repression of Mps1 reduced the mitotic index twofold (Fig. S1 G), which is consistent with previous studies demonstrating that Mps1 is required for SAC function in response to spindle toxins ([@bib26]; [@bib15]; [@bib24]). Time-lapse microscopy confirmed that Mps1-deficient cells failed to arrest when challenged with the Eg5 kinesin inhibitor monastrol (Fig. S1 H). Despite extensive repression, we did not observe centrosome defects, allowing us to focus on Mps1\'s checkpoint functions.

Mps1 restrains anaphase during an unperturbed mitosis
-----------------------------------------------------

To study the role of Mps1 during an unperturbed mitosis, HeLa cells were cotransfected with shRNA vectors and a construct encoding GFP--histone H2B. Transfected cells were analyzed by time-lapse microscopy to determine (1) the time from NEB to alignment of the last chromosome (i.e., NEB to metaphase), (2) the time from alignment of the last chromosome to sister separation (i.e., metaphase to anaphase), and (3) the quality of the segregation process (i.e., scoring for signs of an abnormal mitosis such as anaphase with unaligned chromosomes or anaphase bridges). In controls, metaphase chromosome alignment took ∼22 min, and, after a delay of ∼18 min, anaphase initiated ([Fig. 1, A and B](#fig1){ref-type="fig"}). 92% of the controls completed mitosis normally, exhibiting a substantial delay (\>10 min) after chromosome alignment ([Fig. 1 C](#fig1){ref-type="fig"}). In contrast, Mps1 repression affected both the timing and quality of chromosome segregation. Now, anaphase was initiated much quicker, occurring on average ∼9 min after metaphase ([Fig. 1, A and B](#fig1){ref-type="fig"}). Indeed, ∼23% of Mps1-deficient cells entered anaphase within 10 min of metaphase, whereas only 5% of controls did so ([Fig. 1 C](#fig1){ref-type="fig"}). Furthermore, whereas not a single control cell entered anaphase with an unaligned chromosome, ∼15% of the Mps1-deficient cells entered anaphase with one or more unaligned chromosomes. In addition, ∼9% exhibited anaphase bridges and ∼8% exhibited other mitotic defects. Indeed, only ∼45% of cells completed mitosis normally ([Fig. 1 C](#fig1){ref-type="fig"}). Thus, repression of Mps1 accelerates the onset of anaphase, often before all the chromosomes align at metaphase, indicating that Mps1 is required for SAC function during an unperturbed mitosis. The overall effect of Mps1 RNAi on mitotic timing was modest, reducing the mean time from NEB to anaphase from ∼41 to ∼36 min. In contrast, inhibiting mitotic checkpoint complex components dramatically accelerates mitosis, with NEB-anaphase taking \<15 min ([@bib19]). This suggests that Mps1 is not a component of the APC inhibitor but rather a kinetochore-based sensor responsible for generating the anaphase inhibitor.

![**Mps1 is required for spindle checkpoint function during an unperturbed mitosis.** HeLa cells cotransfected with control or Mps1 shRNA plus a GFP--histone H2B construct were analyzed by time-lapse microscopy. (A) Image sequences showing the time in minutes from when the last chromosome aligns (arrowheads) to anaphase onset. (B) Bar graph quantifying the time taken from NEB to metaphase and from metaphase to anaphase in control and Mps1-deficient cells. Values represent the mean and SEM (error bars) derived from at least 62 cells. (C) Bar graph quantifying mitotic abnormalities observed in control or Mps1-deficient cells. Bar, 5 μm.](jcb1810893f01){#fig1}

Mps1 targets Mad1/Mad2 to kinetochores
--------------------------------------

Experiments with human cells indicate that Mps1 targets Mad1/Mad2 to kinetochores ([@bib17]; [@bib15]), whereas *Xenopus* egg extract data suggest that Mps1 also recruits Bub1, BubR1, and Cenp-E ([@bib1]; [@bib34]; [@bib35]). In our hands, in cells with virtually undetectable levels of Mps1 at kinetochores, localization of aurora B, Bub1, BubR1, Cenp-E, and Cenp-F appeared largely unaffected (Fig. S2 A, available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>; and not depicted). In contrast, kinetochore-bound Mad1 was significantly reduced, and Mad2 was largely absent (Fig. S2 A). To quantitate these effects, pixel intensities were normalized to the anticentromere antibody (ACA) signal and plotted as a percentage of the value derived from unrepressed cells (Fig. S2 B). Consistent with our qualitative assessment, Mps1 RNAi had marginal effects on aurora B, Bub1, BubR1, Cenp-E, and Cenp-F (Fig. S2 B). In contrast, the amount of Mad1 and Mad2 at Mps1-deficient kinetochores was reduced by ∼74% and ∼95%, respectively (Fig. S2 B). Thus, our shRNA-based observations are entirely consistent with previous siRNA observations and together indicate that Mps1 targets Mad1 and Mad2 to kinetochores ([@bib17]; [@bib15]).

Reconstitution of Mps1 function after shRNA-mediated repression
---------------------------------------------------------------

Next, we asked whether an RNAi-resistant Mps1 transgene could rescue the checkpoint defect observed after transfection of the shRNA vector. This would not only confirm that the SAC defect was caused by Mps1 repression, as opposed to an off-target effect, but it would also facilitate structure-function analyses. An Mps1 cDNA was rendered resistant to the shRNA sequence and cloned into an N-terminal GFP-tagged expression construct. Transfecting HeLa cells revealed GFP signal in the cytoplasm and at kinetochores ([Fig. 2 A](#fig2){ref-type="fig"}), which is consistent with Mps1\'s known localization. A stably transfected HeLa line was generated expressing the transgene under tetracycline control ([Fig. 2 B](#fig2){ref-type="fig"}). Transfection of the shRNA vector substantially reduced endogenous Mps1 levels, but the exogenous GFP-tagged protein was still abundant ([Fig. 2 B](#fig2){ref-type="fig"}). We then used time-lapse microscopy to determine the SAC status in Mps1-RNAi cells reconstituted with the wild-type transgene. As described above ([Fig. 1](#fig1){ref-type="fig"}), we scored as normal cells that delayed at metaphase for at least 10 min and then successfully completed chromosome segregation. Cells that initiated anaphase faster or with unaligned chromosomes, displayed lagging chromosomes in anaphase, or exhibited some other mitotic defect were considered abnormal. Although ∼90% of controls completed mitosis normally, only 37% of the Mps1-deficient cells did so ([Fig. 2 C](#fig2){ref-type="fig"}, left). Significantly, induction of the GFP-Mps1 transgene rescued the checkpoint defect, with 74% of the cells now completing a normal mitosis. Indeed, whereas 27% of the Mps1-deficient cells entered anaphase with one or more unaligned chromosomes ([Fig. 2 C,](#fig2){ref-type="fig"}red box), not one reconstituted cell entered anaphase with an unaligned chromosome. This demonstrates that the SAC defect is indeed caused by the repression of Mps1 as opposed to an off-target effect.

![**Mps1 kinase activity is required for spindle checkpoint function.** HeLa cells expressing tet-inducible RNAi-resistant GFP-tagged Mps1 fusions were transfected with shRNA vectors and analyzed by immunofluorescence microscopy, immunoblotting, and time-lapse microscopy. (A) Immunofluorescence images showing kinetochore localization of wild-type Mps1 (WT^R^) and the catalytically inactive D664A mutant (KD^R^). (B) Immunoblot showing repression of the endogenous Mps1 and induction of the RNAi-resistant GFP-tagged proteins. (C) Bar graph quantifying the mitotic phenotypes observed after repression of endogenous Mps1; whereas Mps1 WT^R^ rescues the RNAi defect, Mps1 KD^R^ exacerbates the phenotype. At least 132 cells were scored in each category. Bar, 5 μm.](jcb1810893f02){#fig2}

Mps1 kinase activity is required for checkpoint function
--------------------------------------------------------

To determine whether Mps1 activity is required for SAC function in human cells, we asked whether a catalytically inactive mutant could rescue the RNAi defect. We mutated the aspartic acid in subdomain VII of the catalytic domain to an arginine (Mps1 D664A; [@bib10]), a mutation known to inactivate Mps1 ([@bib14]; [@bib1]). When expressed as a GFP-tagged fusion, this mutant localized to the cytoplasm and kinetochores ([Fig. 2 A](#fig2){ref-type="fig"}). As described in the previous section, we generated stable HeLa cells where the kinase mutant was induced by tetracycline ([Fig. 2 B](#fig2){ref-type="fig"}). As before, these cells were transfected with shRNA constructs, the transgene was induced, and the cells were analyzed by time-lapse microscopy. Importantly, induction of the catalytic mutant failed to rescue the SAC defect ([Fig. 2 C](#fig2){ref-type="fig"}, right). Rather, the catalytic mutant exacerbated the defect, increasing the number of abnormal mitoses from 63 to 80%. Thus, cells in which the endogenous Mps1 has been replaced by a catalytically inactive mutant are checkpoint deficient, demonstrating that Mps1 kinase activity is required for SAC signaling in human cells.

Mps1 kinase activity is required for the kinetochore localization of Mad2
-------------------------------------------------------------------------

To further probe the role of Mps1, we asked whether the kinase mutant could restore Mad1/Mad2 localization. As described above (see section Mps1 targets Mad1/Mad2 to kinetochores), repression of Mps1 reduced kinetochore-bound Mad1 to ∼30% (unpublished data). Induction of wild-type Mps1 and the catalytic mutant restored Mad1 localization to ∼90% and ∼65%, respectively ([Fig. 3, A and B](#fig3){ref-type="fig"}). Thus, reconstitution of cells with a catalytically inactive Mps1 mutant results in substantial recruitment of Mad1 to kinetochores, suggesting that Mps1\'s role in Mad1 localization is only partially dependent on kinase activity. In contrast, kinetochore targeting of Mad2 was largely dependent on Mps1\'s catalytic activity; whereas the wild-type transgene restored kinetochore-bound Mad2 to ∼80%, the amount of kinetochore-bound Mad2 in cells expressing the catalytic mutant was only ∼19% ([Fig. 3, A and B](#fig3){ref-type="fig"}). To highlight this differential effect, we plotted the amount of kinetochore-bound protein restored by the catalytic mutant as a percentage of that restored by wild-type Mps1 ([Fig. 3 C](#fig3){ref-type="fig"}). Although the kinase mutant restored Mad1 levels to ∼75%, Mad2 levels were only restored to ∼25%. Thus, Mps1 kinase activity appears to play a key role in targeting Mad2 to kinetochores.

![**Mps1 kinase activity is required for kinetochore localization of Mad2.** HeLa cells expressing tet-inducible RNAi-resistant GFP-tagged Mps1 fusions were transfected with shRNA vectors, treated with nocodazole for 2 h, and analyzed to detect centromeres (ACA; red) and Mad1 or Mad2 (green). (A) Deconvolved image stacks showing that although Mps1 WT^R^ restores Mad2 localization, Mps1 KD^R^ does not. Enlargements of highlighted (boxed) kinetochores show the presence or absence of either Mad1 or Mad2. (B) Bar graph quantifying Mad1 and Mad2 pixel intensities at kinetochores normalized to the ACA signal. Values represent the mean and SEM (error bars) derived from at least 106 kinetochores from at least nine cells. (C) Bar graph plotting the amount of Mad1 and Mad2 at kinetochores in cells reconstituted with Mps1 KD^R^ as a percentage of those reconstituted with Mps1 WT^R^. Bar, 5 μm.](jcb1810893f03){#fig3}

Chemical genetic--mediated inhibition of Mps1 kinase activity
-------------------------------------------------------------

Although the aforementioned data are consistent with Mps1 kinase activity being required for Mad2 recruitment, we cannot rule out the possibility that the D664A mutation induces a structural effect that prevents Mad2 recruitment independent of any effect on Mps1\'s catalytic activity. Therefore, we turned to chemical genetics to selectively block Mps1 activity using an ATP competitive inhibitor. As described previously in budding yeast Mps1 ([@bib13]), we mutated the gate-keeper residue, replacing methionine 602 with an alanine (Mps1^M602A^), thus rendering Mps1 sensitive to the ATP analogue 1-NM-PP1. We generated a stable cell line expressing GFP-tagged Mps1^M602A^ under tetracycline control; cells were then cotransfected with vectors encoding Mps1 shRNA and GFP--histone H2B and analyzed by time-lapse microscopy to determine checkpoint status. Consistent with the aforementioned data, Mps1 repression inhibited the SAC, with only ∼30% of cells exhibiting a normal mitosis ([Fig. 4 A](#fig4){ref-type="fig"}). Induction of Mps1^M602A^ rescued this defect, with ∼70% of cells completing mitosis normally, indicating that Mps1^M602A^ possesses sufficient catalytic activity to sustain the checkpoint. Significantly, 1-NM-PP1 completely reversed the ability of Mps1^M602A^ to rescue the checkpoint defect ([Fig. 4 A](#fig4){ref-type="fig"}). Furthermore, although Mps1^M602A^ restored the kinetochore localization of Mad2, this was reversed by the addition of 1-NM-PP1 ([Fig. 4, B and C](#fig4){ref-type="fig"}). Thus, because Mps1^M602A^ restores checkpoint function and Mad2 localization, the M602A mutation does not appear to induce a structural defect. However, because 1-NM-PP1 inhibits SAC function and Mad2 recruitment in cells reconstituted with Mps1^M602A^, the data demonstrate that Mps1\'s kinase activity is indeed essential for SAC signaling and Mad2 localization. Note that the kinetochore localization of Mad1 was restored in cells reconstituted with Mps1^M602A^ despite exposure to 1-NM-PP1 (Fig. S3, A and B; available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>), again confirming that Mad1 recruitment is less dependent on Mps1 kinase activity.

![**Chemical genetic inhibition of Mps1 kinase activity inhibits the checkpoint and Mad2 localization.** HeLa cells expressing tet-inducible RNAi-resistant GFP-tagged Mps1 fusions were transfected with shRNA vectors and analyzed by time-lapse microscopy and immunofluorescence. (A) Bar graph quantifying the mitotic phenotypes observed after repression of endogenous Mps1; the ability of Mps1^M602A^ to rescue the RNAi defect is reversed by 1-NM-PP1. (B) Projections of deconvolved image stacks of cells stained to detect centromeres (ACA; red) and Mad2 (green) showing that the ability of Mps1^M602A^ to restore kinetochore localization of Mad2 is reversed by 1-NM-PP1. (C) Bar graph quantifying Mad2 pixel intensities at kinetochores normalized to the ACA signal. Values represent the mean and SEM (error bars) derived from at least 64 kinetochores from at least four cells. Bar, 5 μm.](jcb1810893f04){#fig4}

Pharmacological inhibition of Mps1 kinase activity
--------------------------------------------------

The JNK inhibitor SP600125 overrides the SAC in human cells. SP600125 inhibits Mps1 in vitro, raising the possibility that the checkpoint override is induced by Mps1 inhibition ([@bib24]). However, SP600125 inhibits kinetochore localization of BubR1, a phenomenon not phenocopied by Mps1 RNAi (Fig. S2; [@bib17]; [@bib15]). If SP600125 does indeed inhibit Mps1 activity in cells, our aforementioned observations predict that SP600125 should mislocalize Mad2. However, at concentrations at which SP600125 overrides the SAC (Fig. S3 C), we observed no obvious effect on the kinetochore recruitment of Mad2 (Fig. S3 D). Clarifying this discrepancy will require further analysis, but our data suggest that SAC override induced by SP600125 may not be the result of Mps1 inhibition.

Physiological role of Mps1 kinase activity
------------------------------------------

Using RNAi complementation and chemical genetics, we show that Mps1 kinase activity is required for SAC function during an unperturbed mitosis, and it is differentially required vis-à-vis kinetochore recruitment of Mad1 and Mad2. Because Mad1 is the kinetochore receptor for Mad2 ([@bib21]), Mps1 activity may be required for the Mad1--Mad2 interaction. However, this notion is at odds with experiments showing that the Mad1--Mad2 interaction can be recapitulated in vitro with recombinant proteins (i.e., in the complete absence of Mps1 activity) in a manner that reproduces Mad2\'s in vivo dynamics ([@bib30]).

Although Mad1--Mad2 binding does not require Mps1 in vitro, it is conceivable that in cells, an Mps1-dependent phosphorylation event may enhance the Mad1-dependent recruitment of Mad2, possibly to amplify checkpoint signaling. Indeed, Mps1 can phosphorylate Mad1 in vitro ([@bib11]). Mad2 has been shown to be phosphorylated ([@bib32]), raising the possibility that it is a substrate of Mps1. We do not favor this possibility because phospho-Mad2 does not interact with Mad1 and is checkpoint incompetent, suggesting that Mad2 phosphorylation may be involved in checkpoint inactivation ([@bib32]), which is inconsistent with the notion that Mps1 activity stimulates the SAC. The role for Mps1 activity may be indirect. Repression of two recently identified checkpoint components, Plk-interacting checkpoint helicase and Tao1 (a protein kinase), also dislodges Mad2 from kinetochores despite efficient Mad1 recruitment ([@bib2]; [@bib6]). Tao1 appears to be downstream of Mps1, as kinetochore localization of Mps1 does not require Tao1 ([@bib6]), so Mps1 may influence Mad2 recruitment via Tao1.

An alternative explanation may come from the fact that our observations are derived using an antibody against Mad2. Thus, it is conceivable that the effect observed in Mps1-deficient cells is not caused by the failure to recruit Mad2 but rather an inability to detect it. Indeed, Mad2 adopts either an open or closed conformation, O-Mad2 and C-Mad2, respectively, which are structurally very different ([@bib21]). When bound to Mad1, Mad2 adopts the closed conformation and serves as a template, recruiting O-Mad2 to first form a dimer. O-Mad2 is then handed over to Cdc20 and converted to the closed conformation. Therefore, a key question is whether any given anti-Mad2 antibody can recognize both Mad2 conformers. Interestingly, in interphase, Mad1 and Mad2 localize to nuclear pores ([@bib3]), as does Mps1 ([@bib15]) and the Mad2 inhibitor p31^comet^ (unpublished data). Because p31^comet^ binds the Mad1--C-Mad2 core complex, thus preventing O-Mad2 recruitment ([@bib16]), this suggests that the species present at the nuclear pore is a Mad1--C-Mad2/p31^comet^ complex. Significantly, although we can detect Mad1 and p31^comet^ at nuclear pores, we cannot detect Mad2 (unpublished data), suggesting that the anti-Mad2 antibody does not recognize C-Mad2. Thus, in cells lacking Mps1 kinase activity, C-Mad2 may well be bound to kinetochores but is simply not detectable by the antibody. Alternatively, because Mad2 oligomerizes when expressed in bacteria ([@bib7]), the antibody, which was generated against bacterially expressed Mad2, may only recognize the Mad2 dimer. If the anti-Mad2 antibody recognizes only O-Mad2 or the Mad2 dimer, this, in turn, raises an interesting possibility: perhaps Mps1 kinase activity recruits O-Mad2 to the Mad1--C-Mad2 core complex, possibly by acting on p31^comet^ as opposed to Mad1 and/or Mad2. Although we are currently testing this hypothesis, this issue highlights the need for tools that can distinguish the various conformers of Mad2 in a cell-based assay.

Materials and methods
=====================

Cell lines and drugs
--------------------

hMps1 was PCR amplified from an expressed sequence tag (IMAGE No. 0511705), cloned into a pcDNA5/FRT/TO vector (Invitrogen) modified to contain an N-terminal GFP tag, and mutagenized (QuikChange; Stratagene) to create the D664A-, M602A-, and RNAi-resistant alleles (Table S1, available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>). Vectors were then cotransfected into Flp-In TRex tetracycline transactivator HeLa cells with the Flp recombinase encoding plasmid pOG44 as described previously ([@bib29]). Hygromycin-resistant colonies were pooled and expanded, and transgene expression was induced with 100 ng/ml tetracycline (Sigma-Aldrich). Nocodazole and taxol (both obtained from Sigma-Aldrich) were used at final concentrations of 0.2 μg/ml and 10 μM, respectively. 1NM-PP1 and SP600125 (both purchased from EMD) were used at 10 μM. MG132 (EMD) was used at 20 μM.

shRNA
-----

24 h before transfection, 4 × 10^4^ cells were seeded into a 24-well plate. Vectors encoding shRNA sequences designed to target Mps1 (OriGene; Table S2, available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>) and a plasmid encoding a GFP--histone H2B fusion ([@bib20]) at a ratio of 9:1 were mixed with Lipofectamine Plus (Invitrogen) according to the manufacturer\'s instructions. DNA/lipid complexes were then added to the cells for 7 h. 24 h later, cells were replated onto coverslips, six-well plates, or chamber slides and analyzed 24 h later.

Molecular cell biology
----------------------

The sheep polyclonal antibody SMP1.1 was raised and affinity purified against a GST fusion protein encoding amino acids 18--260 of Mps1 using methods described previously ([@bib28]). Immunoblotting was performed as described previously ([@bib28]; [@bib29]) using the antibodies shown in Table S3 (available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>). For immunofluorescence, cells grown on coverslips were washed in PBS, fixed in 1% formaldehyde for 5 min, quenched in glycine, pH 8.5, and then permeabilized with PBS plus 0.1% Triton X-100 (PBST). Incubation with primary antibodies (Table S3) for 30 min at room temperature was followed by washing with PBST. Incubation with secondary antibodies for 30 min at room temperature was followed by further washing, counterstaining with Hoechst 33358 (1 μg/ml in PBST), and mounting in 90% glycerol and 20 mM Tris-HCl, pH 8.0. Statistical analysis was performed using InStat version 3.0 (GraphPad Software, Inc.). For time-lapse imaging, cells were cultured in multiwell chamber slides (Laboratory Tek; Thermo Fisher Scientific) and analyzed as described previously ([@bib20]).

Cell cycle analysis
-------------------

Mitotic index measurements were determined as described previously ([@bib29]). In brief, loosely attached and adherent cells were harvested and centrifuged onto microscope slides, fixed in 3% formaldehyde in PBS, stained with Hoechst, and mounted as described in the previous section. The state of chromosome condensation was used to score the cells as either mitotic or interphase.

Image acquisition and manipulation
----------------------------------

Immunofluorescence images were acquired at room temperature on a restoration microscope (DeltaVision RT; Applied Precision) using a 100× NA 1.40 Plan Apo objective and the Sedat Quad filter set (Chroma Technology Corp.). The images were collected using a CCD camera (CoolSNAP HQ; Photometrics) with a Z-optical spacing of 0.2 μm. Raw images were then deconvolved using Softworx software (Applied Precision), and maximum intensity projections of these deconvolved images are shown in the results. Time-lapse microscopy was performed on a manual microscope (Axiovert 200; Carl Zeiss, Inc.) equipped with an automated stage (PZ-2000; Applied Scientific Instrumentation) and an environmental control chamber (Solent Scientific), which maintained the cells at 37°C in a humidified stream of 5% CO~2~. Imaging was performed using a 32× NA 0.40 LD A-Plan objective. Shutters, filter wheels, and point visiting were driven by MetaMorph software (MDS Analytical Technologies). Images were taken using a CoolSNAP HQ camera, whereas individual TIFF files were imported into Photoshop (Adobe) for printing or QuickTime (Apple) for videos.

Online supplemental material
----------------------------

Fig. S1 documents the Mps1 reagents used in this study, including the antibody, the GFP-tagged cDNA, and the shRNA constructs. Fig. S2 shows the effect Mps1 repression has on localization of various SAC components. Fig. S3 shows the effect 1-NM-PP1 has on Mad1 localization in cells reconstituted with the Mps1^M602A^ allele. Tables S1, S2, and S3 present the PCR primers, shRNA sequences, and antibodies used in this study, respectively. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200712028/DC1>.
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